Results 261 to 270 of about 1,023,792 (288)
Some of the next articles are maybe not open access.
Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
The promise of conjugate vaccines for Africa
Vaccine, 2007Capsular polysaccharide (PS) vaccines against Neisseria meningitidis and Streptococcus pneumoniae have proven safe and effective. Moreover, experience with N. meningitidis, Haemophilus influenzae type b (Hib) and S. pneumoniae conjugate vaccines has demonstrated that immunogenicity of PS vaccines can be greatly improved by chemical conjugation to a ...
Marie Paule Kieny, F. Marc LaForce
openaire +3 more sources
Polysaccharide Conjugate Typhoid Vaccine
New England Journal of Medicine, 2001There is a growing appreciation of the huge health threat posed by increasingly resistant infectious diseases, especially in tropical areas of the developing world.
Richard L. Guerrant, Margaret Kosek
openaire +3 more sources
PolysaccharicbConjugate Vaccines
2003It was recognized early this century that small molecules, called haptens, can be made immunogenic after conjugation to carrier proteins (1), This principle was thereafter applied successfully to improve the rmmunogenicity of (poly)saccharides (2, 3). We now know that the carrier proteins ensure the involvement of T-helper lymphocytes in the activation
Odo de Weers +6 more
openaire +3 more sources
Pneumococcal Conjugate Vaccines
1995The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire +3 more sources
The pneumococcal protein conjugate vaccines
The Journal of Pediatrics, 2000to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
Timothy R. Peters, Kathryn M. Edwards
openaire +3 more sources
Glycoconjugate vaccines: Principles and mechanisms
Science Translational Medicine, 2018Insight into the mechanisms of glycoconjugate vaccines can improve their efficacy and impact in the future. Bacterial conjugate vaccines are used in infants, adolescents, and the elderly, and they are among the safest and most successful vaccines ...
R. Rappuoli
semanticscholar +1 more source
Conjugate vaccines: practice and theory
Springer Seminars in Immunopathology, 1993Conjugate vaccines have already had a major impact on vaccination of infants against H. influenzae type b. The impact of conjugate vaccines will continue to grow as we apply this technology to other important diseases. The design of these vaccines will become more efficient and rational as we continue to understand the various facets and immunological ...
openaire +3 more sources
Conjugate pneumococcal vaccines: an overview
Medical Journal of Australia, 2000A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk ...
openaire +3 more sources
Immunogenicity of pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 2000Prevention of pneumococcal infections is a public health priority because of the high impact of the disease and because of the increasing problems due to antimicrobial resistance. Traditional vaccines, consisting of purified capsular polysaccharides (PSs) of Streptococcus pneumoniae, are not immunogenic in young children.
openaire +3 more sources